We've supported research to develop the artificial pancreas since the beginning. And we're committed to making this technology a reality for as many people with diabetes as possible.
How the artificial pancreas works
The artificial pancreas, or closed-loop insulin delivery system, continuously monitors blood sugar levels, calculates the amount of insulin required (through a device such as a tablet or mobile phone), and automatically delivers insulin through a pump.
It's known as the 'artificial pancreas' because it monitors and adjusts insulin levels just as the pancreas does in people without diabetes.
The technology has the potential to change lives, making living with diabetes easier and helping people achieve more stable blood sugar levels.
Where it all began
In 1977 we purchased the UK’s first artificial pancreas to help Professor Sir George Alberti stabilise blood sugar levels for people with Type 1 diabetes during surgery and childbirth.
It was the size of a filing cabinet. Since then we've carried on backing research to improve this technology, and have seen exciting advances.
Developing the artificial pancreas for Type 1 diabetes
Our scientist Professor Roman Hovorka at the University of Cambridge worked on the first artificial pancreas prototype. With our funding, he tested it in a world-first trial, which saw 24 people with with Type 1 diabetes using the device in their own homes for a month.
We got the results in 2014. People using the system spent 13.5% more time with their blood sugar levels in the ideal range, compared to people using standard insulin therapy. They also had lower average overnight blood sugar levels without increasing hypos.
Mark Wareham, from Cambridge, has had Type 1 diabetes for 27 years. He took part in the trial in 2013.
“It felt like I was on holiday for the whole month. Waking up almost every day of the trial with blood glucose levels in target range was something new for me, and gave me a sense of stability I don’t get just by using the insulin pump.
“Although it may be a while until the artificial pancreas is available for everyone with Type 1 diabetes, ongoing research like this is taking us closer to breakthrough moments in treating this condition."
Mark Wareham, who benefited from artificial pancreas research
Benefits for pregnant women with Type 1 diabetes
A few years later we backed another world-first trial. Professor Helen Murphy investigated how the artificial pancreas could help women with Type 1 diabetes during pregnancy, where managing the condition is even more challenging.
In 2016, Professor Murphy’s trial showed the device was safe and improved blood sugar control in 16 expectant mums who took part, and, most importantly, led to healthy births and babies.
Laura Carver was one of the women who took part when she was pregnant with Sonny (pictured).
“I felt like I no longer had diabetes because of the artificial pancreas. It was managing my condition and worry away.
"I knew I was giving myself the best chance of a healthy pregnancy. I genuinely believe that without the study we may not have the family that we have today."
Laura Carver, who took part in a life-changing research trial
And people with Type 2 diabetes during hospital stays
We funded Professor Hovorka to carry out one of the first trials of the artificial pancreas with people with Type 2 diabetes. The results, in 2018, showed that the device could transform the care some people with Type 2 diabetes receive while in hospital.
The trial took place at two hospitals in the UK and Switzerland, and involved 136 people with Type 2 diabetes who needed insulin to manage their condition.
Those using the artificial pancreas spent almost 25 per cent more time with blood sugar levels in the target range, compared to people using insulin injections, without an increased risk of hypos.
The artificial pancreas isn’t available yet
The closed-loop artificial pancreas is still being tested in research trials to understand the full benefits.
For now, the closest thing available is the Medtronic MiniMed™ 670G. This is known as a hybrid closed-loop system. The pump automatically adjusts your background, or basal, insulin based on your blood sugar readings. But you still need to tell the device when, and the amount of carbohydrate, you're eating to receive your quick-acting insulin.